Keros Monetizes Hematology Asset In Deal With Takeda
Biotech Will Shift Focus To PAH
Takeda will pay $200m up front for rights to Phase II elritercept for anemia in patients with MDS and myelofibrosis, allowing Keros to extend its cash runway to 2028.
